Traws Pharma, Inc. (TRAW)
0.409
-0.01
(-1.68%)
USD |
NASDAQ |
Oct 13, 10:19
Traws Pharma Enterprise Value : 1.337M for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 1.337M |
| October 09, 2026 | 1.783M |
| October 08, 2026 | 2.319M |
| October 07, 2026 | 2.299M |
| October 06, 2026 | 2.925M |
| October 05, 2026 | 3.170M |
| October 02, 2026 | 3.666M |
| October 01, 2026 | 3.312M |
| September 30, 2026 | 4.052M |
| September 29, 2026 | 4.544M |
| September 28, 2026 | 3.826M |
| September 25, 2026 | 3.585M |
| September 24, 2026 | 3.536M |
| September 23, 2026 | 2.675M |
| September 22, 2026 | 2.620M |
| September 21, 2026 | 2.617M |
| September 18, 2026 | 2.467M |
| September 17, 2026 | 3.162M |
| September 16, 2026 | 3.127M |
| September 15, 2026 | 3.063M |
| September 14, 2026 | 2.908M |
| September 11, 2026 | 3.602M |
| September 10, 2026 | 3.101M |
| September 09, 2026 | 3.231M |
| September 08, 2026 | 3.422M |
| Date | Value |
|---|---|
| September 04, 2026 | 3.385M |
| September 03, 2026 | 3.261M |
| September 02, 2026 | 3.689M |
| September 01, 2026 | 3.994M |
| August 31, 2026 | 4.025M |
| August 28, 2026 | 3.993M |
| August 27, 2026 | 3.924M |
| August 26, 2026 | 4.162M |
| August 25, 2026 | 3.823M |
| August 24, 2026 | 3.536M |
| August 21, 2026 | 3.078M |
| August 20, 2026 | 2.925M |
| August 19, 2026 | 3.231M |
| August 18, 2026 | 3.231M |
| August 17, 2026 | 3.231M |
| August 14, 2026 | 3.704M |
| August 13, 2026 | 4.147M |
| August 12, 2026 | 3.125M |
| August 11, 2026 | 3.246M |
| August 10, 2026 | 3.231M |
| August 07, 2026 | 3.108M |
| August 06, 2026 | 3.215M |
| August 05, 2026 | 3.443M |
| August 04, 2026 | 3.434M |
| August 03, 2026 | 2.186M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.925B |
| Corcept Therapeutics, Inc. | 12.78B |
| Veru, Inc. | 17.90M |
| Johnson & Johnson | 663.40B |
| Eli Lilly & Co. | 1.159T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.054M |
| Total Expenses (Quarterly) | 3.054M |
| EPS Diluted (Quarterly) | -0.1924 |
| Earnings Yield | -564.6% |
| Normalized Earnings Yield | -562.30 |